The association of baseline N-terminal pro-B-type natriuretic peptide with short and long-term prognosis following percutaneous coronary intervention in non-ST segment elevation acute coronary syndrome with multivessel coronary artery disease: a retrospective cohort study

• Published in: BMC cardiovascular disorders Vol. 21; no. 1; pp. 202 - 9
• Main Authors: He, Wen-fei, Jiang, Lei, Chen, Yi-yue, Liu, Yuan-hui, Chen, Peng-yuan, Duan, Chong-yang, Zeng, Li-huan, Fan, Hua-lin, Wei, Xue-biao, Guo, Wei, Chen, Wei, Li, Jun, Li, Wen-sheng, Guo, Zhi-qiang, Liu, Zhi-kai, Tan, Ning, Chen, Ji-yan, He, Peng-cheng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 21.04.2021; BioMed Central; BMC
• Subjects: Acute coronary syndrome; Acute coronary syndromes; Anemia; Angioplasty; Biomarkers; Brain natriuretic peptide; Cardiovascular disease; Care and treatment; Clinical outcomes; Cohort analysis; Coronary artery; Coronary heart disease; Coronary vessels; Death; Diabetes; Health aspects; Heart attacks; Heart diseases; Heart failure; Hospitals; Ischemia; Kidney diseases; Multivessel coronary artery disease; N-terminal pro-B-type natriuretic peptide; Natriuretic peptides; Non-ST segment elevation acute coronary syndrome; Patient outcomes; Patients; Peptides; Prognosis; Statistical analysis; Stroke; Transluminal angioplasty; Variables; China; N-terminal pro-B-type natriuretic peptide; Multivessel coronary artery disease; Non-ST segment elevation acute coronary syndrome
• ISSN: 1471-2261; 1471-2261
• DOI: 10.1186/s12872-021-02010-9

Several studies have shown that N-terminal pro-B-type natriuretic peptide (NT-proBNP) is strongly correlated with the complexity of coronary artery disease and the prognosis of patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS), However, it remains unclear about the prognostic value of NT-proBNP in patients with NSTE-ACS and multivessel coronary artery disease (MCAD) undergoing percutaneous coronary intervention (PCI). Therefore, this study aimed to reveal the relationship between NT-proBNP levels and the prognosis for NSTE-ACS patients with MCAD undergoing successful PCI. This study enrolled 1022 consecutive NSTE-ACS patients with MCAD from January 2010 to December 2014. The information of NT-proBNP levels was available from these patients. The primary outcome was in-hospital all-cause death. In addition, the 3-year follow-up all-cause death was also ascertained. A total of 12 (1.2%) deaths were reported during hospitalization. The 4th quartile group of NT-proBNP (> 1287 pg/ml) showed the highest in-hospital all-cause death rate (4.3%) (P < 0.001). Besides, logistic analyses revealed that the increasing NT-proBNP level was robustly associated with an increased risk of in-hospital all-cause death (adjusted odds ratio (OR): 2.86, 95% confidence interval (CI) = 1.16-7.03, P = 0.022). NT-proBNP was able to predict the in-hospital all-cause death (area under the curve (AUC) = 0.888, 95% CI = 0.834-0.941, P < 0.001; cutoff: 1568 pg/ml). Moreover, as revealed by cumulative event analyses, a higher NT-proBNP level was significantly related to a higher long-term all-cause death rate compared with a lower NT-proBNP level (P < 0.0001). The increasing NT-proBNP level is significantly associated with the increased risks of in-hospital and long-term all-cause deaths among NSTE-ACS patients with MCAD undergoing PCI. Typically, NT-proBN P > 1568 pg/ml is related to the all-cause and in-hospital deaths.